EGFR, KRAS, ERBB2, and BRAF mutations, gene rearrangements (EML4—ALK, ROS1, NTRK1/2, and RET), exon skipping alterations, and gene amplifications (MET) are routinely evaluated in the management of care for NSCLC patients [51]. This evidence concerns the gene RET and non-small cell lung carcinoma.